{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T16:27:09Z","timestamp":1788798429512,"version":"build-2803163510"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2018,5,1]],"date-time":"2018-05-01T00:00:00Z","timestamp":1525132800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"name":"Japan Society for the Promotion of Science Grants-in-Aid for Young Scientists","award":["15K20107"],"award-info":[{"award-number":["15K20107"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Surg Oncol"],"published-print":{"date-parts":[[2018,8]]},"DOI":"10.1245\/s10434-018-6498-2","type":"journal-article","created":{"date-parts":[[2018,5,1]],"date-time":"2018-05-01T17:52:16Z","timestamp":1525197136000},"page":"2484-2491","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":42,"title":["Clinical Role of Programmed Cell Death-1 Expression in Patients with Non-muscle-invasive Bladder Cancer Recurring After Initial Bacillus Calmette\u2013Gu\u00e9rin Therapy"],"prefix":"10.1245","volume":"25","author":[{"given":"Keishiro","family":"Fukumoto","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eiji","family":"Kikuchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuji","family":"Mikami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nozomi","family":"Hayakawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuhiro","family":"Matsumoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoya","family":"Niwa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mototsugu","family":"Oya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,5,1]]},"reference":[{"key":"6498_CR1","doi-asserted-by":"publisher","first-page":"3887","DOI":"10.1002\/j.1460-2075.1992.tb05481.x","volume":"11","author":"Y Ishida","year":"1992","unstructured":"Ishida Y, Agata Y, Shibahara K, Honjo T. Induced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death. EMBO J. 1992;11:3887\u201395.","journal-title":"EMBO J"},{"key":"6498_CR2","doi-asserted-by":"publisher","first-page":"1027","DOI":"10.1084\/jem.192.7.1027","volume":"192","author":"GJ Freeman","year":"2000","unstructured":"Freeman GJ, Long AJ, Iwai Y, et al. Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation. J Exp Med. 2000;192:1027\u201334.","journal-title":"J Exp Med"},{"key":"6498_CR3","doi-asserted-by":"publisher","first-page":"2517","DOI":"10.1056\/NEJMe1205943","volume":"366","author":"A Ribas","year":"2012","unstructured":"Ribas A. Tumor immunotherapy directed at PD-1. N Engl J Med. 2012;366:2517\u20139.","journal-title":"N Engl J Med"},{"key":"6498_CR4","doi-asserted-by":"publisher","first-page":"4800","DOI":"10.1158\/1078-0432.CCR-08-0731","volume":"14","author":"SA Boorjian","year":"2008","unstructured":"Boorjian SA, Sheinin Y, Crispen PL, et al. T-cell coregulatory molecule expression in urothelial cell carcinoma: clinicopathologic correlations and association with survival. Clin Cancer Res. 2008;14:4800\u20138.","journal-title":"Clin Cancer Res"},{"key":"6498_CR5","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1007\/s10549-013-2581-3","volume":"139","author":"S Muenst","year":"2013","unstructured":"Muenst S, Soysal SD, Gao F, Obermann EC, Oertli D, Gillanders WE. The presence of programmed death 1 (PD-1)-positive tumor-infiltrating lymphocytes is associated with poor prognosis in human breast cancer. Breast Cancer Res Treat. 2013;139:667\u201376.","journal-title":"Breast Cancer Res Treat"},{"key":"6498_CR6","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1007\/s00262-014-1519-x","volume":"63","author":"S Sun","year":"2014","unstructured":"Sun S, Fei X, Mao Y, et al. PD-1(+) immune cell infiltration inversely correlates with survival of operable breast cancer patients. Cancer Immunol Immunother. 2014;63:395\u2013406.","journal-title":"Cancer Immunol Immunother"},{"key":"6498_CR7","doi-asserted-by":"publisher","first-page":"1757","DOI":"10.1158\/1078-0432.CCR-06-2599","volume":"13","author":"RH Thompson","year":"2007","unstructured":"Thompson RH, Dong H, Lohse CM, Leibovich BC, Blute ML, Cheville JC, Kwon ED. PD-1 is expressed by tumor-infiltrating immune cells and is associated with poor outcome for patients with renal cell carcinoma. Clin Cancer Res. 2007;13:1757\u201361.","journal-title":"Clin Cancer Res"},{"key":"6498_CR8","doi-asserted-by":"publisher","first-page":"1321","DOI":"10.7314\/APJCP.2014.15.3.1321","volume":"15","author":"YH Wang","year":"2014","unstructured":"Wang YH, Cao YW, Yang XC, Niu HT, Sun LJ, Wang XS, Liu J. Effect of TLR4 and B7-H1 on immune escape of urothelial bladder cancer and its clinical significance. Asian Pac J Cancer Prev. 2014;15:1321\u201326.","journal-title":"Asian Pac J Cancer Prev"},{"key":"6498_CR9","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/j.ejso.2013.08.023","volume":"40","author":"E Xylinas","year":"2014","unstructured":"Xylinas E, Robinson BD, Kluth LA, et al. Association of T-cell co-regulatory protein expression with clinical outcomes following radical cystectomy for urothelial carcinoma of the bladder. Eur J Surg Oncol. 2014;40:121\u20137.","journal-title":"Eur J Surg Oncol."},{"key":"6498_CR10","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1007\/s12032-015-0501-6","volume":"32","author":"J Zhang","year":"2015","unstructured":"Zhang J, Fang W, Qin T, et al. Co-expression of PD-1 and PD-L1 predicts poor outcome in nasopharyngeal carcinoma. Med Oncol. 2015;32:86.","journal-title":"Med Oncol"},{"key":"6498_CR11","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1016\/j.urology.2005.08.066","volume":"66","author":"AM Nieder","year":"2005","unstructured":"Nieder AM, Brausi M, Lamm D, O\u2019Donnell M, Tomita K, Woo H, Jewett MA. Management of stage T1 tumors of the bladder: International Consensus Panel. Urology. 2005;66:108\u201325.","journal-title":"Urology."},{"key":"6498_CR12","doi-asserted-by":"publisher","first-page":"7252","DOI":"10.1158\/1078-0432.CCR-04-0713","volume":"10","author":"RL Camp","year":"2004","unstructured":"Camp RL, Dolled-Filhart M, Rimm DL. X-tile: a new bio-informatics tool for biomarker assessment and outcome-based cut-point optimization. Clin Cancer Res. 2004;10:7252\u20139.","journal-title":"Clin Cancer Res"},{"key":"6498_CR13","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1016\/j.clon.2017.10.019","volume":"30","author":"N Hayakawa","year":"2018","unstructured":"Hayakawa N, Kikuchi E, Mikami S, Fukumoto K, Oya M. The role of PD-1 positivity in the tumour nest on clinical outcome in upper tract urothelial carcinoma patients treated with radical nephroureterectomy. Clin Oncol (R Coll Radiol). 2018;30:e1\u20138.","journal-title":"Clin Oncol (R Coll Radiol)"},{"key":"6498_CR14","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1111\/j.1365-2249.1995.tb05560.x","volume":"99","author":"AM Jackson","year":"1995","unstructured":"Jackson AM, Alexandroff AB, Kelly RW, et al. Changes in urinary cytokines and soluble intercellular adhesion molecule-1 (ICAM-1) in bladder cancer patients after bacillus Calmette-Guerin (BCG) immunotherapy. Clin Exp Immunol. 1995;99:369\u201375.","journal-title":"Clin Exp Immunol"},{"key":"6498_CR15","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1046\/j.1365-2249.1999.00756.x","volume":"115","author":"K Taniguchi","year":"1999","unstructured":"Taniguchi K, Koga S, Nishikido M, Yamashita S, Sakuragi T, Kanetake H, Saito Y. Systemic immune response after intravesical instillation of Bacillus Calmette\u2013Guerin (BCG) for superficial bladder cancer. Clin Exp Immunol. 1999;115:131\u20135.","journal-title":"Clin Exp Immunol"},{"key":"6498_CR16","doi-asserted-by":"publisher","first-page":"964","DOI":"10.1097\/01.ju.0000073852.24341.4a","volume":"170","author":"A Bohle","year":"2003","unstructured":"Bohle A, Brandau S. Immune mechanisms in Bacillus Calmette\u2013Guerin immunotherapy for superficial bladder cancer. J Urol. 2003;170:964\u20139.","journal-title":"J Urol"},{"key":"6498_CR17","doi-asserted-by":"publisher","first-page":"1706","DOI":"10.1097\/01.ju.0000062605.92268.c6","volume":"169","author":"HW Herr","year":"2003","unstructured":"Herr HW, Dalbagni G. Defining Bacillus Calmette\u2013Guerin refractory superficial bladder tumors. J Urol. 2003;169:1706\u20138.","journal-title":"J Urol."},{"key":"6498_CR18","doi-asserted-by":"publisher","first-page":"1088","DOI":"10.1016\/j.eururo.2012.08.055","volume":"62","author":"DR Yates","year":"2012","unstructured":"Yates DR, Brausi MA, Catto JW, et al. Treatment options available for Bacillus Calmette\u2013Guerin failure in non-muscle-invasive bladder cancer. Eur Urol. 2012;62:1088\u201396.","journal-title":"Eur Urol"},{"key":"6498_CR19","doi-asserted-by":"publisher","first-page":"E508","DOI":"10.1111\/j.1464-410X.2012.11194.x","volume":"110","author":"K Matsumoto","year":"2012","unstructured":"Matsumoto K, Kikuchi E, Shirakawa H, et al. Risk of subsequent tumour recurrence and stage progression in Bacillus Calmette\u2013Guerin relapsing non-muscle-invasive bladder cancer. BJU Int. 2012;110:E508\u201313.","journal-title":"BJU Int"},{"key":"6498_CR20","doi-asserted-by":"publisher","first-page":"E216","DOI":"10.1111\/j.1464-410X.2011.10894.x","volume":"110","author":"H Shirakawa","year":"2012","unstructured":"Shirakawa H, Kikuchi E, Tanaka N, Matsumoto K, Miyajima A, Nakamura S, Oya M. Prognostic significance of Bacillus Calmette\u2013Guerin failure classification in non-muscle-invasive bladder cancer. BJU Int. 2012;110:E216\u201321.","journal-title":"BJU Int"},{"key":"6498_CR21","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1593\/tlo.13256","volume":"6","author":"MJ Kang","year":"2013","unstructured":"Kang MJ, Kim KM, Bae JS, et al. Tumor-infiltrating PD1-positive lymphocytes and FoxP3-positive regulatory T cells predict distant metastatic relapse and survival of clear cell renal cell carcinoma. Transl Oncol. 2013;6:282\u20139.","journal-title":"Transl Oncol"},{"key":"6498_CR22","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1016\/S1470-2045(17)30007-4","volume":"18","author":"ER Plimack","year":"2017","unstructured":"Plimack ER, Bellmunt J, Gupta S, et al. Safety and activity of pembrolizumab in patients with locally advanced or metastatic urothelial cancer (KEYNOTE-012): a non-randomised, open-label, phase 1b study. Lancet Oncol. 2017;18:212\u201320.","journal-title":"Lancet Oncol"},{"key":"6498_CR23","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1111\/iju.12232","volume":"21","author":"F Roghmann","year":"2014","unstructured":"Roghmann F, Trinh QD, Braun K, von Bodman C, Brock M, Noldus J, Palisaar J. Standardized assessment of complications in a contemporary series of European patients undergoing radical cystectomy. Int J Urol. 2014;21:143\u20139.","journal-title":"Int J Urol"},{"key":"6498_CR24","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1016\/j.eururo.2013.05.027","volume":"64","author":"B Ehdaie","year":"2013","unstructured":"Ehdaie B, Sylvester R, Herr HW. Maintenance Bacillus Calmette\u2013Guerin treatment of non-muscle-invasive bladder cancer: a critical evaluation of the evidence. Eur Urol. 2013;64:579\u201385.","journal-title":"Eur Urol"}],"container-title":["Annals of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1245\/s10434-018-6498-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-018-6498-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-018-6498-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,1]],"date-time":"2019-05-01T00:03:38Z","timestamp":1556669018000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1245\/s10434-018-6498-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,5,1]]},"references-count":24,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2018,8]]}},"alternative-id":["6498"],"URL":"https:\/\/doi.org\/10.1245\/s10434-018-6498-2","relation":{},"ISSN":["1068-9265","1534-4681"],"issn-type":[{"value":"1068-9265","type":"print"},{"value":"1534-4681","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,5,1]]},"assertion":[{"value":"18 October 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 May 2018","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}